You are here: Industry Insights > pembrolizumab

News List

First person enrolled in Phase I oncolytic virus trial europeanpharmaceuticalreview
March 04, 2021
The Phase I/IIa trial of BT-001 will assess the safety and efficacy of the virus’ dual mode of action in solid tumours.
NICE recommends Keytruda (pembrolizumab) for treatment of HNSCC europeanpharmaceuticalreview
October 26, 2020
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
FDA Approves Keytruda for First-Line Treatment of MSI-H/dMMR Colorectal Cancer americanpharmaceuticalreview
July 09, 2020
The Food and Drug Administration (FDA) approved pembrolizumab (KEYTRUDA, Merck) for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma americanpharmaceuticalreview
July 03, 2020
The Food and Drug Administration (FDA) approved pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
FDA Approves Pembrolizumab for TMB-H Solid Tumors americanpharmaceuticalreview
June 28, 2020
The Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) ...
MimiVax SurVaxM, Pembrolizumab Study Opens for Recurrent Glioblastoma Patients americanpharmaceuticalreview
June 10, 2020
MimiVax announced a clinical collaboration to assess the combination of SurVaxM and pembrolizumab.
FDA Approves New Dosing Regimen for Pembrolizumab americanpharmaceuticalreview
May 05, 2020
The Food and Drug Administration (FDA) granted accelerated approval to a new dosing regimen of 400 mg every six weeks for pembrolizumab (KEYTRUDA, Merck) across all currently approved adult indications.
Study reveals immunotherapy after chemotherapy slows metastatic bladder cancer expresspharma
April 13, 2020
The randomised Phase 2 trial tested immunotherapy known as pembrolizumab in 108 patients after they were treated with platinum-based chemotherapy.
NICE fails to recommend pembrolizumab in final draft guidance europeanpharmaceuticalreview
March 17, 2020
The UK NICE has not found pembrolizumab cost-effective for use on the NHS, after a review of evidence collected while the drug was available via the Cancer Drugs Fund.
FDA Approves Pembrolizumab for Bladder Cancer americanpharmaceuticalreview
January 09, 2020
The Food and Drug Administration (FDA) approved pembrolizumab (KEYTRUDA, Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk ...

Previous page 1 2 3 4 Next page